Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
A new validated staging system for AL amyloidosis (AL International Staging System (AL-ISS)) incorporates longitudinal strain (≥-9%) and has a Stage IIIC, which defines an ultra-poor risk subgroup with 7-month median OS.”
Title: A new validated staging system for AL amyloidosis with Stage IIIC defining ultra-poor risk: AL International Staging System (AL-ISS)
Authors: Jahanzaib Khwaja, Amy A Kirkwood, Paolo Milani, Binoy Yohannan, Foteini Theodorakakou, Flores Weverling, Valeria Di Simone, Sriram Ravichandran, Shaji Kumar, Ioannis Petropoulos, Roberta Mussinelli, Oliver Cohen, Marish IFJ Oerlemans, Eli Muchtar, Kimon Stamatelopoulos, Helen J Lachmann, Julian D Gillmore, Alexandros Briasoulis, Morie Gertz, Carol Whelan, Lucia Venneri, Marianna Fontana, Shameem Mahmood, Rahel Schwotzer, Monique C Minnema, Angela Dispenzieri, Giovanni Palladini, Efstathios Kastritis, and Ashutosh Wechalekar.
You can read the Full Article in the Journal of Clinical Oncology.
You can find more posts featuring Robert Orlowski on OncoDaily.
